News | November 07, 2006

Aortic Tissue Heart Valve Moves Closer to Market Approval

An initial review of the premarket approval application for the ATS 3f(R) Aortic Bioprosthesis Heart Valve has been completed by The Center for Devices and Radiological Health FDA.

The ATS 3f(R) brand — by ATS Medical, Minneapolis, MN — encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology.

Company chairman and president says it’s an important milestone along the path to U.S. market approval of the device.

"The $700 million tissue heart valve market is the fastest growing segment within the $1.2 billion heart valve therapies marketplace,” said Michael Dale.” We believe that ATS 3f tissue heart valve technologies offer added value and therapeutic options for clinicians and patients, and we look forward to working closely with the FDA to bring these products to market."

For more information visit www.atsmedical.com.


Related Content

News | Heart Valve Technology

May 9, 2023 — Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of ...

Home May 09, 2023
Home
News | Heart Valve Technology

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to ...

Home February 28, 2023
Home
News | Heart Valve Technology

January 23, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 23, 2023
Home
News | Heart Valve Technology

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has given the approval to market to The Edwards ...

Home January 02, 2023
Home
News | Heart Valve Technology

December 29, 2022 — The Smidt Heart Institute at Cedars-Sinai was named a Mitral Valve Repair Reference Center, a ...

Home December 29, 2022
Home
News | Heart Valve Technology

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

Home December 14, 2022
Home
News | Heart Valve Technology

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
News | Heart Valve Technology

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

Home October 18, 2022
Home
News | Heart Valve Technology

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

Home October 18, 2022
Home
News | Heart Valve Technology

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
Subscribe Now